Alebund Closes RMB 550M In Series C Financing Round
07 Jan 2025 //
#N/A
Alebund`s Investigational Drug AP303 Receives FDA ODD for the Treatment of ADPKD
29 Mar 2024 //
PR NEWSWIRE
Alebund Reports Update for AP306 (EOS789)
13 Dec 2023 //
PR NEWSWIRE
LAV’s Xia parlays gap in kidney therapies into China start-up
12 Oct 2021 //
BIOCENTURY
Shanghai biotech tackling kidney disease gets another round of cash
14 Sep 2021 //
ENDPTS
Alebund Pharmaceuticals Raises $54.5M in Series B+ Financing
13 Sep 2021 //
PRNEWSWIRE